TREATMENT PATTERNS, HEALTHCARE RESOURCE USE, AND COSTS AMONG US PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFRm) METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC) AFTER DISCONTINUATION OF OSIMERTINIB

被引：0
|
作者：
Moore-Schiltz, L. [1 ]
McMorrow, D. [2 ]
Chambers, J. [1 ]
Pulungan, Z. [1 ]
Teigland, C. [1 ]
Marrett, L. [3 ]
机构：
[1] Inovalon, Bowie, MD USA
[2] Inovalon, Scarborough, ME USA
[3] Daiichi Sankyo Inc, Basking Ridge, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE371
引用
收藏
页码：S125 / S126
页数：2
相关论文
共 50 条
  • [21] Real-world utilization of liquid biopsy for epidermal growth factor receptor (EGFR) testing in patients with metastatic non-small cell lung cancer (mNSCLC)
    Shah, Anne
    Apple, Jon
    Ryan, Debra L.
    de Silva, Kevin
    Cai, Ling
    Shenolikar, Rahul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 402 - 402
  • [22] Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
    Xu, Haiyan
    Chen, Hengqi
    Kong, Jianxin
    Zhang, Ye
    Liu, Shan
    Yang, Guangjian
    Yang, Lu
    Wang, Yan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (11)
  • [23] First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US
    Vieira, M. Cecilia
    Duncan, K.
    Hsu, W. -C.
    Ross, R.
    Benjumea, D.
    Vlahiotis, A.
    Li, B.
    Wilner, K. D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E36 - E36
  • [24] Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Brouns, A.
    Veelen, A. V.
    Veerman, M.
    Steendam, C.
    Dursun, S.
    Croes, S.
    Dingemans, A-M. C.
    Hendriks, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
  • [25] Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Johnson, BE
    Jänne, PA
    CANCER RESEARCH, 2005, 65 (17) : 7525 - 7529
  • [26] PREDICTORS OF EPIDERMAL GROWTH FACTOR (EGFR) TESTING AMONG PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) TREATED IN THE REAL-WORLD SETTING
    Vasudevan, A.
    Sura, T.
    English, S.
    Wang, B.
    Varughese, P.
    Katzen, H.
    VALUE IN HEALTH, 2023, 26 (06) : S218 - S218
  • [27] Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer
    Nicole, Princic
    Elizabeth, Marrett
    Jacqueline, Kwong Winghan
    Donna, Mcmorrow
    Hana, Schwartz
    Janakiraman, Subramanian
    FUTURE ONCOLOGY, 2024, 20 (24) : 1753 - 1764
  • [28] Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR plus ) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients
    Tavara, B.
    Lopez, L.
    Medina, S.
    Garrido, M. L.
    Lopez, A.
    Lopez, M.
    Vallejo Pascual, M. E.
    Tain, P. Diz
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S642 - S642
  • [29] The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
    Subramanian, Janakiraman
    Fernandes, Ancilla W.
    Laliberte, Francois
    Pavilack, Melissa
    DerSarkissian, Maral
    Duh, Mei Sheng
    LUNG CANCER, 2019, 138 : 131 - 138
  • [30] The Role of Osimertinib in Treatment Naive Epidermal Growth Factor Receptor-Mutated Stage IIIB or IV Non-Small-Cell Lung Cancer Patients
    Uprety, Dipesh
    Bista, Amir
    Vallatharasu, Yazhini
    Arjyal, Lubina
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2018, 12
12345